NCT03669757View on ClinicalTrials.gov

Clinical Trial to Assess Safety, Tolerability and the Pharmacodynamic Effect of Different Concentrations of a New Anti-inflammatory Substance in Subjects With Chronic Plaque Psoriasis

PHASE1CompletedINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

September 27, 2018

Primary Completion Date

February 1, 2019

Study Completion Date

February 1, 2019

Conditions
Psoriasis Vulgaris
Interventions
DRUG

LEO 134310

Active substance: LEO 134310 is a compound in development at LEO Pharma A/S

DRUG

LEO 134310

Active substance: LEO 134310 is a compound in development at LEO Pharma A/S

DRUG

LEO 134310

Active substance: LEO 134310 is a compound in development at LEO Pharma A/S

DRUG

LEO 134310

Active substance: LEO 134310 is a compound in development at LEO Pharma A/S

DRUG

LEO 134310 vehicle

Active substance: none

DRUG

0.1% betamethasone valerate ointment (class III steroid)

Active substance: betamethasone valerate

Trial Locations (2)

19055

Investigational Site, Schwerin

20095

Investigational Site, Hamburg

Sponsors

Lead Sponsor

LEO Pharma
All Listed Sponsors
lead

LEO Pharma

INDUSTRY